Inhibition of TGFβ1-mediated PAI-1 induction by oltipraz through selective interruption of Smad 3 activation

Cytokine

Volumn 35, Issue 5-6, 2006, Pages 284-294

  Cho, Il Je ^a   Kim, Sun Hwa ^a   Kim, Sang Geon ^a  

^a Tumor Microenvironment Global Core Research Center   (South Korea)

Author keywords

Oltipraz; PAI 1; Smad 2; Smad 3; TGF 1

Indexed keywords

ANTIBODY; DNA; OLTIPRAZ; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FIBROBLAST; IMMUNOCHEMISTRY; IMMUNOPHARMACOLOGY; INHIBITION KINETICS; LIVER CIRRHOSIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACODYNAMICS; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMICALLY INDUCED DISORDER; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL NUCLEUS; HUMANS; LIVER CIRRHOSIS; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 36749097988     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.10.001     Document Type: Article

References (56)

1. Kensler T.W., Egner P.A., Dolan P.M., Groopman J.D., and Roebuck B.D. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 47 (1987) 4271-4277
2. Wang J.S., Shen X., He X., Zhu Y.R., Zhang B.C., Wang J.B., et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 91 (1999) 347-354
3. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
4. Kang K.W., Kim Y.G., Cho M.K., Bae S.K., Kim C.W., Lee M.G., et al. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16 (2002) 1988-1990
5. Letterio J.J., and Bottinger E.P. TGF-beta knockout and dominant-negative receptor transgenic mice. Miner Electrolyte Metab 24 (1998) 161-167
6. Massague J., and Chen Y.G. Controlling TGF-beta signaling. Genes Dev 14 (2000) 627-644
7. Vassalli J.D., Sappino A.P., and Belin D. The plasminogen activator/plasmin system. J Clin Invest 88 (1991) 1067-1072
8. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57 (2000) 25-40
9. Lijnen H.R., and Collen D. Mechanisms of plasminogen activation by mammalian plasminogen activators. Enzyme 40 (1988) 90-96
10. He C., Wilhelm S.M., Pentland A.P., Marmer B.L., Grant G.A., Eisen A.Z., et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86 (1989) 2632-2636
11. Murphy G., Atkinson S., Ward R., Gavrilovic J., and Reynolds J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 667 (1992) 1-12
12. Andreasen P.A., Georg B., Lund L.R., Riccio A., and Stacey S.N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68 (1990) 1-19
13. Seki T., Imai H., Uno S., Ariga T., and Gelehrter T.D. Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver. Thromb Haemost 75 (1996) 801-807
14. Fitzpatrick T.E., and Graham C.H. Stimulation of plasminogen activator inhibitor-1 expression immortalized human trophoblast cells cultured under low levels of oxygen. Exp Cell Res 245 (1998) 155-162
15. Hiromi H., Kazo K., Kohei U., Toshinori N., Ichiro T., Yue L.Q., et al. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thromb Res 111 (2003) 301-309
16. Zhang L.P., Takahara T., Yata Y., Furui K., Jin B., Kawada N., et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cell. J Hepatol 31 (1999) 703-711
17. Bissell D.M., Wang S.S., Wang W.R., and Roll F.J. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 96 (1995) 447-455
18. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., and Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17 (1998) 3091-3100
19. Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H., et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86 (1996) 543-552
20. Graff J.M., Bansal A., and Melton D.A. Xenopus Mad proteins transduce distinct subsets of signals for the TGFβ superfamily. Cell 85 (1996) 479-487
21. Piek E., Heldin C.H., and ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13 (1999) 2105-2124
22. Vyberg M., Junge J., and Horn T. Detection of early zone 3 liver fibrosis in chronic alcoholics. A comparison of four connective tissue staining methods. Acta Pathol Microbiol Immunol Scand 95 (1987) 11-16
23. Park E.Y., Cho I.J., and Kim S.G. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res 64 (2004) 3701-3713
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 27 (1970) 680-685
25. Kang K.W., Cho I.J., Lee C.H., and Kim S.G. Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. J Natl Cancer Inst 95 (2003) 53-66
26. Grinberg A.V., and Kerppola T. Both Max and TFE3 cooperate with Smad proteins to bind the plasminogen activator inhibitor-1 promoter, but they have opposite effects on transcriptional activity. J Biol Chem 278 (2003) 11227-11236
27. Reisdorf P., Lawrence D.A., Sivan V., Klising E., and Martin M.T. Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis. Am J Pathol 159 (2001) 263-272
28. Guo B., Inoki K., Isono M., Mori H., Kanasaki K., Sugimoto T., et al. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-β in rat mesangial cells. Kidney Int 68 (2005) 972-984
29. Zhang X., Yang J., Li Y., and Liu Y. Both Sp1 and Smad participate in mediating TGF-β1-induced HGF receptor expression in renal epithelial cells. Am J Physiol Renal Physiol 288 (2005) F16-F26
30. Mostert V., Dreher I., Kohrle J., Wolff S., and Abel J. Modulation of selenoprotein P expression by TGF-β1 is mediated by Smad proteins. BioFactors 14 (2001) 135-142
31. von Gersdorff G., Susztak K., Rezvani F., Bitzer M., Liang D., and Bottinger E.P. Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J Biol Chem 275 (2000) 11320-11326
32. Jonk L.J., Itoh S., Heldin C.H., ten Dijke P., and Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 273 (1998) 21145-21152
33. Pinzani M., Marra F., and Carloni V. Signal transduction in hepatic stellate cells. Liver 18 (1998) 2-13
34. Baroni G.S., D'Ambrosio L., Curto P., Casini A., Mancini R., Jezequel A.M., et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23 (1996) 1189-1199
35. Podor T.J., and Loskutoff D.J. Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor in the extracellular matrix of transforming growth factor-beta-activated endothelial cells. Ann N Y Acad Sci 667 (1992) 46-49
36. Lyon C.J., and Hsueh W.A. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115 (2003) 62S-68S
37. Eitzman D.T., Westrick R.J., Xu Z., Tyson J., and Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96 (2000) 4212-4215
38. Oda T., Jung Y.O., Kim H.S., Cai X., Lopez-Guisa J.M., Ikeda Y., et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60 (2001) 587-596
39. Juhan-Vague I., Alessi M.C., and Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34 (1991) 457-462
40. Liu C., Gaca M.D., Swenson E.S., Vellucci V.F., Reiss M., and Wells R.G. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 278 (2003) 11721-11728
41. Inagaki Y., Nemoto T., Nakao A., Dijke P., Kobayashi K., Takehara K., et al. Interaction between GC box binding factors and Smad proteins modulates cell lineage-specific alpha 2(I) collagen gene transcription. J Biol Chem 276 (2001) 16573-16579
42. Inagaki Y., Mamura M., Kanamaru Y., Greenwel P., Nemoto T., Takehara K., et al. Constitutive phosphorylation and nuclear localization of Smad 3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 187 (2001) 117-123
43. Piek E., Ju W.J., Heyer J., Escalante-Alcalde D., Stewart C.L., Weinstein M., et al. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 276 (2001) 19945-19953
44. Vindevoghel L., Lechleider R.J., Kon A., de Caestecker M.P., Uitto J., Roberts A.B., et al. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene promoter by transforming growth factor beta. Proc Natl Acad Sci USA 95 (1998) 14769-14774
45. Feng X.H., Lin X., and Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19 (2000) 5178-5193
46. Wrana J.L. Regulation of Smad activity. Cell 100 (2000) 189-192
47. Frey R.S., and Mulder K.M. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells. Cancer Res 57 (1997) 628-633
48. Watanabe H., de Caestecker M.P., and Yamada Y. Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem 276 (2001) 14466-14473
49. Hirashima Y., Kobayashi H., Suzuki M., Tanaka Y., Kanayama N., and Terao T. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem 278 (2003) 26793-26802
50. Hayashida T., Decaestecker M., and Schnaper H.W. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 17 (2003) 1576-1578
51. Furukawa F., Matsuzaki K., Mori S., Tahashi Y., Yoshida K., Sugano Y., et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38 (2003) 879-889
52. Uemura M., Swenson E.S., Gaca M.D., Giordano F.J., Reiss M., and Wells R.G. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 16 (2005) 4214-4224
53. Liu X., Wang W., Hu H., Tang N., Zhang C., Liang W., et al. Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm Res 23 (2006) 82-89
54. Liu X.J., Ruan C.M., Gong X.F., Li X.Z., Wang H.L., Wang M.W., et al. Antagonism of transforming growth factor-beta signaling inhibits fibrosis-related genes. Biotechnol Lett 27 (2005) 1609-1615
55. Lee S.J., and Kim S.G. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-β for GSTA2 gene transactivation. Mol Pharmacol 69 (2006) 385-396
56. Zauberman A., Lapter S., and Zipori D. Smad proteins suppress CCAAT/enhancer-binding protein (C/EBP)β- and STAT3-mediated transcriptional activation of the haptoglobin promoter. J Biol Chem 276 (2001) 24719-24725